SGP’s CEO Hassan: Putting Money Where His Mouth Is

After watching his stock lose more than one-fifth of its value this week, Schering-Plough CEO Fred Hassan apparently decided the shares are on sale. This morning the company issued a press release announcing Hassan (pronounced Haa-sun, not the commonly mispronounced Huh-sahn) will shell out $2 million of his own money to buy SGP shares on the open market.

And it’s specifically related to the fallout from the ENHANCE study[1]of Schering and Merck’s cholesterol drug Vytorin that has battered both companies’ stocks this week.

His bet appears to be paying off. As I write this, SGP is the only major American drug stock that’s trading higher. albeit just a fraction. Nonetheless, it’s the first gain for SGP this week.

In the release, which you can read in its entirety here[2], Hassan is quoted as saying, “The media interpretations of the top-line ENHANCE trial results, and the resulting stock price reaction, have been deeply troubling. I firmly believe in VYTORIN and ZETIA.” Vytorin is a combo of Zocor and Zetia. “Our mission is ‘To earn trust, every day’ and this personal stock purchase reflects my faith that, together, our 50,000 dedicated Schering-Plough employees can accomplish that mission,” Hassan said.

Interestingly, the press release says Hassan wanted to literally buy the stock yesterday when it closed at $21.62. But the lawyers told him it’d be better to wait until after the company reports earnings on February 12th and researchers present the detailed data from ENHANCE at the American College of Cardiology conference in late March.

Hassan bought more than $4.5 million worth of SGP shares more than four years ago. Given that he has to wait awhile to make this purchase, this strikes me as a smart PR ploy to try to move the needle in the meantime on the beaten down shares.

Credit Suisse big pharma analyst Catherine Arnold calls this week’s selloff a “frenzy” and is telling clients in a research note entitled, “Vytorin News Overdone,” to follow Hassan’s lead. She says, “…investors are overestimating the impact this study will have on Vytorin sales.” CS has done investment banking for MRK and SGP and wants to do more. And Arnold or someone on her team lives with someone who works at Schering.

Merck reports earnings on January 30th. This is the first time in quite some time–at least, as far as I can remember–that MRK and SGP have not reported their numbers on the same day because of the joint venture on Vytorin. Again, SGP won’t report until Feb. 12th. And, by the way, Pfizer just put out a press release announcing Chairman and CEO Jeff Kindler will meet with Wall Street on March 5th. That’s gonna be a biggie.

Questions?  Comments?  Pharma@cnbc.com[3]

References

  1. ^ the fallout from the ENHANCE study (www.cnbc.com)
  2. ^ which you can read in its entirety here (www.scheringplough.com)
  3. ^ Pharma@cnbc.com (www.cnbc.com)

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Franchisers – operating a content network of several thousand sites while federating 100+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $100M in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Contact us to learn how we can help you with your online marketing and/or site maintenance.

Share